ArticleInsights into imaging2026
Incorporating parenchymal heterogeneity into FLIS to improve MRI-based liver function assessment.
Article in Insights into imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Imaging of MASLD: clinical standards and novel methods.Diabetologia · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess the correlation between the functional liver imaging score (FLIS) and FibroScan MATERIALS AND
methodsThis retrospective single-centre study included 113 patients who underwent FibroScan
resultsA total of 113 patients (67 men; mean age 56.6 ± 13.5 years) were evaluated. Inter-reader agreement was excellent for FLIS (ICC 0.994; 95% CI: 0.975-1.000), heterogeneity (ICC 0.949; 95% CI: 0.901-0.984), and FLIS-H (ICC 0.974; 95% CI: 0.957-0.989). FLIS showed significant negative correlations with Child-Pugh (ρ = -0.2664, p = 0.0087), ALBI (ρ = -0.3076, p = 0.0022), and fibrosis stage (ρ = -0.3207, p < 0.001). FLIS-H demonstrated stronger correlations with Child-Pugh (ρ = -0.4167, p < 0.001), ALBI (ρ = -0.5243, p < 0.001), MELD (ρ = -0.2360, p = 0.020), and fibrosis stage (ρ = -0.5270, p < 0.001). Steiger's z-test confirmed that correlations were significantly improved with FLIS-H for ALBI (z = -3.03, p = 0.0025), Child-Pugh (z = -2.01, p = 0.045), and fibrosis stage (z = -2.90, p = 0.0038).
conclusionFLIS correlates significantly with fibrosis stage and clinical scores. Incorporating parenchymal heterogeneity into FLIS enhances these associations and may provide a superior method for liver assessment. CRITICAL RELEVANCE: This study introduces a modified FLIS version (FLIS-H) that integrates parenchymal heterogeneity and demonstrates superior correlation with elastography-derived fibrosis stages and clinical scoring systems, offering a practical improvement for non-invasive assessment in routine practice. KEY POINTS: FLIS has no reported correlation with elastography-based liver fibrosis staging. Parenchymal heterogeneity is not included as a parameter in the standard FLIS. Integrating heterogeneity improves correlation with fibrosis stage and clinical scores. FLIS-H enables fast, reliable, structure-function liver assessment in clinical radiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.